Selexys Pharmaceuticals Corporation

Although the US FDA has been largely able keep up its review functions throughout the government shutdown so far, it remained a quiet week of drug development announcements. Here's your news in brief:

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging bioph

Start-up RallyBio Inc. , which launched on April 25 with $37m in Series A venture capital, is starting out with a dream team of executives with experience developing, launching and marketing therapie

Emmaus Life Sciences Inc. envisages modest pricing of $11,000 to $18,000 yearly for Endari , which is a breakthrough in terms of being the first drug approved for sickle cell disease in almost 20 y